Cargando…
Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system (CNS) that represents one of the first causes of neurological disability in young adults. Although the pathogenesis of MS is still unclear, an autoimmune mechanism has been demonstrated. According to this eviden...
Autores principales: | Gasperini, Claudio, Ruggieri, Serena, Pozzilli, Carlo |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940747/ https://www.ncbi.nlm.nih.gov/pubmed/20856685 |
Ejemplares similares
-
Multiple sclerosis patients treated with cladribine tablets: expert opinion on practical management after year 4
por: Centonze, Diego, et al.
Publicado: (2023) -
Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod
por: Gasperini, Claudio, et al.
Publicado: (2013) -
The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
por: Hermann, Robert, et al.
Publicado: (2018) -
The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review
por: Rammohan, Kottil, et al.
Publicado: (2020) -
Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis
por: Prosperini, Luca, et al.
Publicado: (2021)